Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced that the accelerator for the MEVION S250i Proton Therapy System® was delivered on July 28, 2022, to Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China. This milestone commences the system installation at Tongji Hospital’s proton therapy center, the first of its kind in Central China.
The system at Tongji Hospital features Mevion’s industry leading HYPERSCAN® Pencil Beam Scanning (PBS) technology and Adaptive Aperture® pMLC. This powerful duo provides faster and more precise targeted dose delivery to tumors thus, minimizing the damage to surrounding healthy tissue and organs at risk. The system also integrates a diagnostic quality CT imaging system and a surface tracking system for high precision patient positioning and intra-fraction motion management.
Founded in 1900, Tongji Hospital currently treats over 6 million patients annually. It has developed into one of the world’s largest and most powerful oncology medical teaching and research facilities, and the recently opened Optics Valley Tongji Children’s Hospital is located on the same campus as the new proton therapy center. In addition to the Mevion system, the new proton therapy center will also be equipped with a cutting-edge whole-body PET/CT imaging system. Tongji Hospital has also built a second proton vault, making it China’s first proton center applying the One Plus One multi-system installation approach. This approach gives cancer centers the flexibility to add a second system in the future to correspond to the growth of patient volume and clinical expertise. By doing a staged installation approach, financial burdens are significantly reduced at the start of the clinical proton therapy program, and the risk of technology obsolescence is mitigated greatly.
“Mevion is excited to start the system installation at world-class Tongji Hospital, and we look forward to a continued partnership that will give patients in Central China much-needed access to proton therapy,” said Tina Yu, Ph.D., chief executive officer and president of Mevion. “We are proud of our technology that provides advanced cancer treatment to patients and allows hospitals to expand their proton therapy program at their own pace.”
*Mevion is actively seeking regulatory approval from the National Medical Products Administration (NMPA) in China.